FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Cy Stein

Research Profile

Chemicals & Drugs

Anatomy

Disorders

Prostatic Neoplasms

Living Beings

Mouse

Physiology

Concepts & Ideas

Co-author Network

Publications

TOP 3
Sumanta K Pal; Junmi Saikia; Cy A Stein; Virginia Sun; Przemyslaw Twardowski; Jonathan Yamzon; Courtney Carmichael; Betty Ferrell; Paul Frankel; Joann Hsu; Kim Margolin
Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors.
Sumanta K Pal; Cy A Stein; Oliver Sartor
Enzalutamide for the treatment of prostate cancer.
Jensen Hu; Paulo G Bergerot; JoAnn Hsu; Cy A Stein; Bertram E Yuh; Sumanta K Pal
Preoperative therapy for localized prostate cancer: a comprehensive overview.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Cy Stein (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sumanta K Pal; Junmi Saikia; Cy A Stein; Virginia Sun; Przemyslaw Twardowski; Jonathan Yamzon; Courtney Carmichael; Betty Ferrell; Paul Frankel; Joann Hsu; Kim Margolin
Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors.
Clinical genitourinary cancer 2013;11(2):121-7.
2013: Sumanta K Pal; Cy A Stein; Oliver Sartor
Enzalutamide for the treatment of prostate cancer.
Expert opinion on pharmacotherapy 2013;14(5):679-85.
2013: Jensen Hu; Paulo G Bergerot; JoAnn Hsu; Cy A Stein; Bertram E Yuh; Sumanta K Pal
Preoperative therapy for localized prostate cancer: a comprehensive overview.
Maturitas 2013;74(1):3-9.
2012: Sumanta K Pal; Cy A Stein
Prolonged therapy with cabazitaxel in an octogenarian with metastatic castration-resistant prostate cancer.
Clinical genitourinary cancer 2012;10(4):274-6.
2012: Harris S Soifer; Naira Souleimanian; Anatoliy M Voskresenskiy; Sijian Wu; Filiz Kisaayak Collak; Bekir Cinar; Cy A Stein
Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.
The Journal of biological chemistry 2012;287(6):3777-87.
2012: Naira Souleimanian; Masad J Damha; Glen F Deleavey; Harris S Soifer; Katrin Tiemann; Sijian Wang; Cy A Stein
Antisense 2'-Deoxy, 2'-Fluroarabino Nucleic Acids (2'F-ANAs) Oligonucleotides: In Vitro Gymnotic Silencers of Gene Expression Whose Potency Is Enhanced by Fatty Acids.
Molecular therapy. Nucleic acids 2012;1():e43.
2012: Harris S Soifer; Bo Hansen; Anja Hoeg; Troels Koch; Johnathan Lai; Henrik Oerum; Cy A Stein
Silencing of gene expression by gymnotic delivery of antisense oligonucleotides.
Methods in molecular biology (Clifton, N.J.) 2012;815():333-46.
2011: Cy A Stein; SANJAY GOEL
Therapeutic oligonucleotides: the road not taken.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(20):6369-72.
2010: Cy A Stein; J Bo Hansen; Johnathan Lai; SiJian Wu; Anatoliy Voskresenskiy; Anja Høg; Jesper Worm; Maj Hedtjärn; Naira Souleimanian; Paul S Miller; Harris S Soifer; Daniela Castanotto; Luba Benimetskaya; Henrik Ørum; Troels Koch
Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents.
Nucleic acids research 2010;38(1):e3.
2009: Sanjiv S Agarwala; Ulrich Keilholz; Erard Gilles; Agop Y Bedikian; Jane Wu; Richard Kay; Cy A Stein; Loretta M Itri; Stefan Suciu; Alexander M M Eggermont
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
European journal of cancer (Oxford, England : 1990) 2009;45(10):1807-14.
2009: Cy A Stein; Sijian Wu; Anatoliy M Voskresenskiy; Jin-Feng Zhou; Joongho Shin; Paul S Miller; Naira Souleimanian; Luba Benimetskaya
G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(8):2797-807.
2008: Luba Benimetskaya; Sijian Wu; Anatoliy M Voskresenskiy; Cinara Echart; Jin-Feng Zhou; Joongho Shin; Massimo Iacobelli; Paul Richardson; Kanyalakshmi Ayyanar; Cy A Stein
Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease.
Blood 2008;112(10):4343-52.
2008: Cy A Stein; Marco Colombini
Specific VDAC inhibitors: phosphorothioate oligonucleotides.
Journal of bioenergetics and biomembranes 2008;40(3):157-62.
2007: Wenzhi Tan; Yue-Hin Loke; Cy A Stein; Paul S Miller; Marco Colombini
Phosphorothioate oligonucleotides block the VDAC channel.
Biophysical journal 2007;93(4):1184-91.
2007: Hong Zhao; Ping Peng; Clifford Longley; Yue Zhang; Virna Borowski; Mary Mehlig; Prasanna Reddy; Jing Xia; Gerrit Borchard; Jack Lipman; Luba Benimetskaya; Cy A Stein
Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy.
Journal of controlled release : official journal of the Controlled Release Society 2007;119(2):143-52.
2007: Cy A Stein; SANJAY GOEL; Reza Ghavamian
Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy.
Investigational new drugs 2007;25(3):277-8.
2007: Wenzhi Tan; Johnathan C Lai; Paul S Miller; Cy A Stein; Marco Colombini
Phosphorothioate oligonucleotides reduce mitochondrial outer membrane permeability to ADP.
American journal of physiology. Cell physiology 2007;292(4):C1388-97.
2007: Johnathan C Lai; Bob D Brown; Anatoliy M Voskresenskiy; Stefan Vonhoff; Sven Klussman; Wenzhi Tan; Marco Colombini; Risini D Weeratna; Paul S Miller; Luba Benimetskaya; Cy A Stein
Comparison of d-g3139 and its enantiomer L-g3139 in melanoma cells demonstrates minimal in vitro but dramatic in vivo chiral dependency.
Molecular therapy : the journal of the American Society of Gene Therapy 2007;15(2):270-8.
2007: Cy A Stein
Genasense: it ain't over till the fat lady sings.
Oligonucleotides 2007;17(4):345-8.
2006: Luba Benimetskaya; Kanyalakshmi Ayyanar; Noah Kornblum; Daniela Castanotto; John Rossi; Sijian Wu; Johnathan Lai; Bob D Brown; Natalia Popova; Paul S Miller; Harilyn McMicken; Yin Chen; Cy A Stein
Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(16):4940-8.
2006: Johnathan C Lai; Wenzhi Tan; Luba Benimetskaya; Paul S Miller; Marco Colombini; Cy A Stein
A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(19):7494-9.
2006: Emily M Anderson; Paul S Miller; D Ilsley; William Marshall; Anastasia Khvorova; Cy A Stein; Luba Benimetskaya
Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature.
Cancer gene therapy 2006;13(4):406-14.
2006: Noah Kornblum; Kanyalakshmi Ayyanar; Luba Benimetskaya; Paul Richardson; Massimo Iacobelli; Cy A Stein
Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action.
Oligonucleotides 2006;16(1):105-14.
2006: Volker Gekeler; Petra Gimmnich; Hans-Peter Hofmann; Carola Grebe; Michaela Römmele; Astrid Leja; Monika Baudler; Luba Benimetskaya; Barbara Gonser; Uwe Pieles; Thomas Maier; Thomas Wagner; Karl Sanders; James F Beck; Guido Hanauer; Cy A Stein
G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Oligonucleotides 2006;16(1):83-93.
2005: Cy A Stein; Luba Benimetskaya; Sridhar Mani
Antisense strategies for oncogene inactivation.
Seminars in oncology 2005;32(6):563-72.
2005: Luba Benimetskaya; Johnathan C Lai; Anastasia Khvorova; Sijian Wu; Paul S Miller; Cy A Stein
Induction of apoptosis by G3139 in melanoma cells.
Annals of the New York Academy of Sciences 2005;1058():235-45.
2005: Johnathan C Lai; Luba Benimetskaya; Anastasia Khvorova; Sijian Wu; Emily Hua; Paul S Miller; Cy A Stein
Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells.
Molecular cancer therapeutics 2005;4(2):305-15.
2005: Luba Benimetskaya; Paul S Miller; Cy A Stein
518A2 melanoma cells are protected by G3139 and other antineoplastic agents against the cytotoxic effects of DTIC.
Oligonucleotides 2005;15(3):206-14.
2004: Luba Benimetskaya; Johnathan C Lai; Anastasia Khvorova; Sijian Wu; Emily Hua; Paul S Miller; Li-Ming Zhang; Cy A Stein
Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8371-9.
2004: Luba Benimetskaya; Timo Wittenberger; Cy A Stein; Hans-Peter Hofmann; Claudia Weller; Johnathan C Lai; Paul S Miller; Volker Gekeler
Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3678-88.
2004: Anthony J Raffo; Johnathan C Lai; Cy A Stein; Paul S Miller; Steven Scaringe; Anastasia Khvorova; Luba Benimetskaya
Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen).
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):3195-206.
2003: Irina Lebedeva; Devanand Sarkar; Zao-Zhong Su; Shinichi Kitada; Paul Dent; Cy A Stein; John C Reed; Paul B Fisher
Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24.
Oncogene 2003;22(54):8758-73.
2003: Johnathan C Lai; Luba Benimetskaya; Regina M Santella; Qiao Wang; Paul S Miller; Cy A Stein
G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner.
Molecular cancer therapeutics 2003;2(10):1031-43.
2003: WenJing Liu; Anca Bulgaru; Missak Haigentz; Cy A Stein; Roman Perez-Soler; Sridhar Mani
The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics.
Current medicinal chemistry. Anti-cancer agents 2003;3(3):217-23.
2003: Gwen L Nichols; Cy A Stein
Modulation of the activity of Bcl-2 in Waldenstrom's macroglobulinemia using antisense oligonucleotides.
Seminars in oncology 2003;30(2):297-9.
2003: Laixin Wang; Ramesh K Prakash; Cy A Stein; Richard K Koehn; Duane E Ruffner
Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.
Antisense & nucleic acid drug development 2003;13(3):169-89.
2002: Nathalie Dias; Cy A Stein
Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 2002;54(3):263-9.
2002: Luba Benimetskaya; Cy A Stein
Antisense therapy: recent advances and relevance to prostate cancer.
Clinical prostate cancer 2002;1(1):20-30.
2002: Maria Vilenchik; Anthony J Raffo; Luba Benimetskaya; David Shames; Cy A Stein
Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents.
Cancer research 2002;62(7):2175-83.
2002: Nathalie Dias; Cy A Stein
Antisense oligonucleotides: basic concepts and mechanisms.
Molecular cancer therapeutics 2002;1(5):347-55.
2002: Luba Benimetskaya; Nancy Guzzo-Pernell; Su-Ting Liu; Johnathan C H Lai; Paul S Miller; Cy A Stein
Protamine-fragment peptides fused to an SV40 nuclear localization signal deliver oligonucleotides that produce antisense effects in prostate and bladder carcinoma cells.
Bioconjugate chemistry 2002;13(2):177-87.
2001: Luba Benimetskaya; Paul S Miller; S Benimetsky; Anna Maciaszek; Piotr Guga; Serge L Beaucage; Andrzej Wilk; Andrzej Grajkowski; A L Halperin; Cy A Stein
Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
Molecular pharmacology 2001;60(6):1296-307.
2001: Cy A Stein
The experimental use of antisense oligonucleotides: a guide for the perplexed.
The Journal of clinical investigation 2001;108(5):641-4.
2001: Zhaozhong Su; Irina Lebedeva; Rahul V Gopalkrishnan; NI Goldstein; Cy A Stein; J C Reed; Paul Dent; Paul B Fisher
A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(18):10332-7.
2001: Maria Koziolkiewicz; E Gendaszewska; Maria Maszewska; Cy A Stein; Wojciech J Stec
The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5'-nucleotidase.
Blood 2001;98(4):995-1002.
2001: Myriam Berton; Priscilla Turelli; Didier Trono; Cy A Stein; Eric Allémann; Robert Gurny
Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles.
Pharmaceutical research 2001;18(8):1096-101.
2001: Cy A Stein
Antisense that comes naturally.
Nature biotechnology 2001;19(8):737-8.
2001: Irina Lebedeva; Anthony J Raffo; R Rando; J Ojwang; P Cossum; Cy A Stein
Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides.
The Journal of urology 2001;166(2):461-9.
2001: Maria Vilenchik; L Benimetsky; A Kolbanovsky; Paul S Miller; Cy A Stein
Evidence for higher-order structure formation by the c-myb 18-mer phosphorothioate antisense (codons 2-7) oligodeoxynucleotide: potential relationship to antisense c-myb inhibition.
Antisense & nucleic acid drug development 2001;11(2):87-97.
2001: Irina Lebedeva; Cy A Stein
Antisense oligonucleotides: promise and reality.
Annual review of pharmacology and toxicology 2001;41():403-19.
2000: Irina Lebedeva; R Rando; J Ojwang; P Cossum; Cy A Stein
Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.
Cancer research 2000;60(21):6052-60.
2000: Irina Lebedeva; Luba Benimetskaya; Cy A Stein; Maria Vilenchik
Cellular delivery of antisense oligonucleotides.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 2000;50(1):101-19.
2000: Irina Lebedeva; Cy A Stein
Antisense oligonucleotides in cancer: recent advances.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2000;13(3):195-216.
2000: Cy A Stein
Is irrelevant cleavage the price of antisense efficacy?
Pharmacology & therapeutics 2000;85(3):231-6.
2000: M Ma; Luba Benimetskaya; Irina Lebedeva; J Dignam; G Takle; Cy A Stein
Intracellular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences.
Nature biotechnology 2000;18(1):58-61.
2000: Luba Benimetskaya; J Tonkinson; Cy A Stein
Determination of cellular internalization of fluoresceinated oligonucleotides.
Methods in enzymology 2000;313():287-97.
1999: Cy A Stein
Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments.
Biochimica et biophysica acta 1999;1489(1):45-52.
1999: AD Simon; Kenneth Giedd; Allan Schwartz; W Wang; J Sun; H J Chen; Charles C Marboe; Cy A Stein; LeRoy E Rabbani
Porous balloon delivery of S-dC28 does not prevent restenosis in the porcine coronary artery model of balloon injury.
Antisense & nucleic acid drug development 1999;9(6):549-53.
1999: Myriam Berton; Eric Allémann; Cy A Stein; Robert Gurny
Highly loaded nanoparticulate carrier using an hydrophobic antisense oligonucleotide complex.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 1999;9(2):163-70.
1999: HQ Miao; Michael Elkin; E Aingorn; Rivka Ishai-Michaeli; Cy A Stein; Israel Vlodavsky
Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides.
International journal of cancer. Journal international du cancer 1999;83(3):424-31.
1999: Cy A Stein
Mechanisms of action of taxanes in prostate cancer.
Seminars in oncology 1999;26(5 Suppl 17):3-7.
1999: M Lee; AD Simon; Cy A Stein; LeRoy E Rabbani
Antisense strategies to inhibit restenosis.
Antisense & nucleic acid drug development 1999;9(5):487-92.
1999: Z Khaled; Y Ho; Luba Benimetskaya; Richard J Deckelbaum; Cy A Stein
Omega-6 polyunsaturated fatty acid-stimulated cellular internalization of phosphorothioate oligodeoxynucleotides: evidence for protein kinase C-zeta dependency.
Biochemical pharmacology 1999;58(3):411-23.
1999: H Yamamoto; Jae-Won Soh; T Monden; MG Klein; L M Zhang; Haim Shirin; Nadir Arber; N Tomita; Ira Schieren; Cy A Stein; I Bernard Weinstein
Paradoxical increase in retinoblastoma protein in colorectal carcinomas may protect cells from apoptosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1805-15.
1999: Myriam Berton; Luba Benimetskaya; Eric Allémann; Cy A Stein; Robert Gurny
Uptake of oligonucleotide-loaded nanoparticles in prostatic cancer cells and their intracellular localization.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 1999;47(2):119-23.
1999: Cy A Stein
Keeping the biotechnology of antisense in context.
Nature biotechnology 1999;17(3):209.
1998: Luba Benimetskaya; G B Takle; Maria Vilenchik; Irina Lebedeva; Paul S Miller; Cy A Stein
Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides.
Nucleic acids research 1998;26(23):5310-7.
1998: Leonid Yakubov; Yuri Kit; Vladimir A Richter; A Y Andreeva; V N Karamyshev; Cy A Stein; Valentin V Vlassov
The extracellular domain of CD4 receptor possesses a protein kinase activity.
FEBS letters 1998;431(1):45-8.
1998: Q Y Liu; M A Rubin; CO Omene; S Lederman; Cy A Stein
Fas ligand is constitutively secreted by prostate cancer cells in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(7):1803-11.
1998: W Wang; HJ Chen; J Sun; Luba Benimetskaya; Allan Schwartz; Paul J Cannon; Cy A Stein; LeRoy E Rabbani
A comparison of guanosine-quartet inhibitory effects versus cytidine homopolymer inhibitory effects on rat neointimal formation.
Antisense & nucleic acid drug development 1998;8(3):227-36.
1998: Cy A Stein
How to design an antisense oligodeoxynucleotide experiment: a consensus approach.
Antisense & nucleic acid drug development 1998;8(2):129-32.
1997: W Wang; HJ Chen; Allan Schwartz; Paul J Cannon; Cy A Stein; LeRoy E Rabbani
Inhibitory nonsequence-specific effects of cytidine homopolymers on in vivo neointimal formation.
Antisense & nucleic acid drug development 1997;7(6):559-66.
1997: Q Y Liu; Cy A Stein
Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):2039-46.
1997: Luba Benimetskaya; Michael Berton; A Kolbanovsky; S Benimetsky; Cy A Stein
Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kappaB p65) 'antisense' oligodeoxynucleotide.
Nucleic acids research 1997;25(13):2648-56.
1997: P Rockwell; W J O'Connor; K King; NI Goldstein; L M Zhang; Cy A Stein
Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(12):6523-8.
1997: Cy A Stein
Controversies in the cellular pharmacology of oligodeoxynucleotides.
Antisense & nucleic acid drug development 1997;7(3):207-9.
1997: W Wang; HJ Chen; MK Warshofsky; Allan Schwartz; Cy A Stein; LeRoy E Rabbani
Effects of S-dC28 on vascular smooth muscle cell adhesion and plasminogen activator production.
Antisense & nucleic acid drug development 1997;7(2):101-7.
1997: Luba Benimetskaya; John D Loike; Z Khaled; G Loike; Samuel C. Silverstein; Long Cao; Joseph B El-Khoury; T Q Cai; Cy A Stein
Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein.
Nature medicine 1997;3(4):414-20.
1997: Cy A Stein
Controversies in the cellular pharmacology of oligodeoxynucleotides.
Ciba Foundation symposium 1997;209():79-89; discussion 89-93.
1996: W Wang; HJ Chen; Allan Schwartz; Paul J Cannon; Cy A Stein; LeRoy E Rabbani
Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides.
The Journal of clinical investigation 1996;98(2):443-50.
1996: Cy A Stein
Exploiting the potential of antisense: beyond phosphorothioate oligodeoxynucleotides.
Chemistry & biology 1996;3(5):319-23.
1996: Cy A Stein
Phosphorothioate antisense oligodeoxynucleotides: questions of specificity.
Trends in biotechnology 1996;14(5):147-9.
1996: Alan M Gewirtz; Cy A Stein; Peter M Glazer
Facilitating oligonucleotide delivery: helping antisense deliver on its promise.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(8):3161-3.
1996: Cy A Stein
Antitumor effects of antisense phosphorothioate c-myc oligodeoxynucleotides: a question of mechanism.
Journal of the National Cancer Institute 1996;88(7):391-3.
1996: Z Khaled; Luba Benimetskaya; R Zeltser; T Khan; H W Sharma; R Narayanan; Cy A Stein
Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides.
Nucleic acids research 1996;24(4):737-45.
1996: S Lederman; G Sullivan; Luba Benimetskaya; I Lowy; K Land; Z Khaled; A M Cleary; Leonid Yakubov; Cy A Stein
Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independency of G-tetrad formation.
Antisense & nucleic acid drug development 1996;6(4):281-9.
1996: F Eckstein; A M Krieg; Cy A Stein; S Agrawal; S Beaucage; Phillip Cook; S Crooke; M J Gait; A Gewirtz; C Hélène; Paul S Miller; R Narayanan; A Nicolin; P Nielsen; E Ohtsuka; H Seliger; W Stec; D Tidd; R Wagner; J Zon
On the quality control of antisense oligonucleotides.
Antisense & nucleic acid drug development 1996;6(3):149.
1996: J L Tonkinson; Cy A Stein
Antisense oligodeoxynucleotides as clinical therapeutic agents.
Cancer investigation 1996;14(1):54-65.
1995: H W Sharma; JA Sokoloski; J R Perez; J Y Maltese; A C Sartorelli; Cy A Stein; G Nichols; Z Khaled; N T Telang; R Narayanan
Differentiation of immortal cells inhibits telomerase activity.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(26):12343-6.
1995: W P Bishop; J Lin; Cy A Stein; A M Krieg
Interruption of a transforming growth factor alpha autocrine loop in Caco-2 cells by antisense oligodeoxynucleotides.
Gastroenterology 1995;109(6):1882-9.
1995: Luba Benimetskaya; J L Tonkinson; Maria Koziolkiewicz; Boleslaw Karwowski; P Guga; R Zeltser; Wojciech J Stec; Cy A Stein
Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent.
Nucleic acids research 1995;23(21):4239-45.
1995: Cy A Stein
Does antisense exist?
Nature medicine 1995;1(11):1119-21.
1995: G B Henderson; Cy A Stein
5'-Cholesteryl-phosphorothioate oligodeoxynucleotides: potent inhibition of methotrexate transport and antagonism of methotrexate toxicity in cells containing the reduced-folate carrier.
Nucleic acids research 1995;23(18):3726-31.
1995: Zao-Zhong Su; S Yemul; Cy A Stein; Paul B Fisher
c-fos is a positive regulator of carcinogen enhancement of adenovirus transformation.
Oncogene 1995;10(10):2037-49.
1995: Cy A Stein; T M Khan; Z Khaled; J L Tonkinson
Cell surface binding and cellular internalization properties of suramin, a novel antineoplastic agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(5):509-17.
1995: M A Guvakova; Leonid Yakubov; I Vlodavsky; J L Tonkinson; Cy A Stein
Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix.
The Journal of biological chemistry 1995;270(6):2620-7.
1995: Z Khaled; D Rideout; Kevin O'Driscoll; Daniel P Petrylak; A Cacace; R Patel; L C Chiang; S Rotenberg; Cy A Stein
Effects of suramin-related and other clinically therapeutic polyanions on protein kinase C activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(1):113-22.
1995: A M Krieg; Cy A Stein
Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?
Antisense research and development 1995;5(4):241.
1994: Cy A Stein; R Narayanan
Antisense oligodeoxynucleotides.
Current opinion in oncology 1994;6(6):587-94.
1994: J L Tonkinson; Cy A Stein
Patterns of intracellular compartmentalization, trafficking and acidification of 5'-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells.
Nucleic acids research 1994;22(20):4268-75.
1994: J R Perez; Y Li; Cy A Stein; S Majumder; A van Oorschot; R Narayanan
Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(13):5957-61.
1994: R V La Rocca; M R Cooper; R Danesi; Cy A Stein; C E Myers
Suramin therapy for malignant thymoma: a case report.
European journal of cancer (Oxford, England : 1990) 1994;30A(5):718-9.
1994: Cy A Stein; A M Krieg
Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides.
Antisense research and development 1994;4(2):67-9.
1994: Denis Archambault; Cy A Stein; J S Cohen
Phosphorothioate oligonucleotides inhibit the replication of lentiviruses and type D retroviruses, but not that of type C retroviruses.
Archives of virology 1994;139(1-2):97-109.
1994: J L Tonkinson; M Guvakova; Z Khaled; J Lee; Leonid Yakubov; W S Marshall; M H Caruthers; Cy A Stein
Cellular pharmacology and protein binding of phosphoromonothioate and phosphorodithioate oligodeoxynucleotides: a comparative study.
Antisense research and development 1994;4(4):269-78.
1993: Leonid Yakubov; Z Khaled; L M Zhang; Alemseged Truneh; V Vlassov; Cy A Stein
Oligodeoxynucleotides interact with recombinant CD4 at multiple sites.
The Journal of biological chemistry 1993;268(25):18818-23.
1993: Cy A Stein; Y C Cheng
Antisense oligonucleotides as therapeutic agents--is the bullet really magical?
Science (New York, N.Y.) 1993;261(5124):1004-12.
1993: Cy A Stein
Suramin: a novel antineoplastic agent with multiple potential mechanisms of action.
Cancer research 1993;53(10 Suppl):2239-48.
1993: Cy A Stein; J L Tonkinson; L M Zhang; Leonid Yakubov; J Gervasoni; R Taub; S A Rotenberg
Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells.
Biochemistry 1993;32(18):4855-61.
1993: Arthur M Krieg; J Tonkinson; S Matson; Q Zhao; M Saxon; L M Zhang; U Bhanja; Leonid Yakubov; Cy A Stein
Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(3):1048-52.
1993: Cy A Stein; A M Cleary; Leonid Yakubov; S Lederman
Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120.
Antisense research and development 1993;3(1):19-31.
1992: Cy A Stein; J Tonkinson; J Gervasoni; L M Zhang; S Krishna; R Taub; S Fields; Thomas Delohery; S Rotenberg
Mechanistic aspects of the interaction of polyanionic oligodeoxynucleotides with HL60 cells.
Annals of the New York Academy of Sciences 1992;660():313-4.
1992: Cy A Stein
Anti-sense oligodeoxynucleotides--promises and pitfalls.
Leukemia 1992;6(10):967-74.
1992: T P Wade; A Kasid; Cy A Stein; R V LaRocca; E R Sargent; L G Gomella; Charles E Myers; W Marston Linehan
Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture.
The Journal of surgical research 1992;53(2):195-8.
1992: W S Marshall; G Beaton; Cy A Stein; M Matsukura; M H Caruthers
Inhibition of human immunodeficiency virus activity by phosphorodithioate oligodeoxycytidine.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(14):6265-9.
1992: R V La Rocca; MR Cooper; Cy A Stein; David R Kohler; M Uhrich; E Weinberger; Charles E Myers
A pilot study of suramin in the treatment of progressive refractory follicular lymphomas.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(7):571-3.
1992: C Myers; M Cooper; Cy A Stein; R LaRocca; McClellan Walther; G Weiss; P Choyke; Nancy A Dawson; S Steinberg; M M Uhrich
Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(6):881-9.
1992: M Saxon; Ira Schieren; L M Zhang; J L Tonkinson; Cy A Stein
Stimulation of calcium influx in HL60 cells by cholesteryl-modified homopolymer oligodeoxynucleotides.
Antisense research and development 1992;2(3):243-50.
1991: Cy A Stein; J L Tonkinson; Leonid Yakubov
Phosphorothioate oligodeoxynucleotides--anti-sense inhibitors of gene expression?
Pharmacology & therapeutics 1991;52(3):365-84.
1991: Ting-Chao Chou; Q Y Zhu; Cy A Stein
Differential alteration of the anti-HIV-1 effect of phosphorothioate oligonucleotide S-dC28 by AZT, interferon-alpha, and dextran sulfate.
AIDS research and human retroviruses 1991;7(11):943-51.
1991: R Pal; S Mumbauer; G Hoke; R Larocca; C Myers; M G Sarngadharan; Cy A Stein
Effect of Evans blue and trypan blue on syncytia formation and infectivity of human immunodeficiency virus type I and type II in vitro.
AIDS research and human retroviruses 1991;7(6):537-43.
1991: M Nakajima; A DeChavigny; C E Johnson; J Hamada; Cy A Stein; Garth L Nicolson
Suramin. A potent inhibitor of melanoma heparanase and invasion.
The Journal of biological chemistry 1991;266(15):9661-6.
1991: R V La Rocca; Cy A Stein; R Danesi; MR Cooper; M Uhrich; Charles E Myers
A pilot study of suramin in the treatment of metastatic renal cell carcinoma.
Cancer 1991;67(6):1509-13.
1991: Cy A Stein; R Pal; Anthony DeVico; G Hoke; S Mumbauer; O Kinstler; M G Sarngadharan; Robert L Letsinger
Mode of action of 5'-linked cholesteryl phosphorothioate oligodeoxynucleotides in inhibiting syncytia formation and infection by HIV-1 and HIV-2 in vitro.
Biochemistry 1991;30(9):2439-44.
1991: Leonid Yakubov; L Yurchenko; M Nechaeva; Elena Y Rykova; V Karaymshev; J Tonkinson; V Vlassov; Cy A Stein
Interaction of oligonucleotides with cellular receptors.
Nucleic acids symposium series 1991;(24):311.
1991: Cy A Stein; Leonid Yakubov; L M Zhang; J Tonkinson
Mode of uptake of 5'-cholesteryl-linked phosphodiester oligodeoxynucleotides in HL60 cells.
Nucleic acids symposium series 1991;(24):155-6.
1991: Cy A Stein; Leonard M Neckers; B C Nair; S Mumbauer; G Hoke; R Pal
Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4.
Journal of acquired immune deficiency syndromes 1991;4(7):686-93.
1990: R V La Rocca; Cy A Stein; R Danesi; Charles E Myers
Suramin, a novel antitumor compound.
The Journal of steroid biochemistry and molecular biology 1990;37(6):893-8.
1990: John C Reed; Cy A Stein; C Subasinghe; S Haldar; C M Croce; S Yum; J Cohen
Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides.
Cancer research 1990;50(20):6565-70.
1990: Adi F Gazdar; H K Oie; C H Shackleton; T R Chen; Timothy Triche; C E Myers; G P Chrousos; Murray F Brennan; Cy A Stein; R V La Rocca
Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis.
Cancer research 1990;50(17):5488-96.
1990: R V La Rocca; Cy A Stein; R Danesi; CA Jamis-Dow; Gary Weiss; Charles E Myers
Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect.
The Journal of clinical endocrinology and metabolism 1990;71(2):497-504.
1990: R V La Rocca; J Meer; R W Gilliatt; Cy A Stein; J Cassidy; Charles E Myers; Marinos C Dalakas
Suramin-induced polyneuropathy.
Neurology 1990;40(6):954-60.
1990: W Y Gao; R N Hanes; M A Vazquez-Padua; Cy A Stein; J S Cohen; Yung-Chi Cheng
Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides.
Antimicrobial agents and chemotherapy 1990;34(5):808-12.
1990: R V La Rocca; Cy A Stein; Charles E Myers
Suramin: prototype of a new generation of antitumor compounds.
Cancer cells (Cold Spring Harbor, N.Y. : 1989) 1990;2(4):106-15.
1989: Cy A Stein; M Matsukura; C Subasinghe; S Broder; J S Cohen
Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV.
AIDS research and human retroviruses 1989;5(6):639-46.
1989: K Mori; Claudine Boiziau; C Cazenave; M Matsukura; C Subasinghe; J S Cohen; S Broder; Jean-Jacques Toulmé; Cy A Stein
Phosphoroselenoate oligodeoxynucleotides: synthesis, physico-chemical characterization, anti-sense inhibitory properties and anti-HIV activity.
Nucleic acids research 1989;17(20):8207-19.
1989: W Y Gao; Cy A Stein; J S Cohen; Ginger E Dutschman; Yung-Chi Cheng
Effect of phosphorothioate homo-oligodeoxynucleotides on herpes simplex virus type 2-induced DNA polymerase.
The Journal of biological chemistry 1989;264(19):11521-6.
1989: C Cazenave; Cy A Stein; N Loreau; Nguyen T Thuong; Leonard M Neckers; C Subasinghe; Claude Hélène; J S Cohen; Jean-Jacques Toulmé
Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides.
Nucleic acids research 1989;17(11):4255-73.
1989: M Matsukura; G Zon; K Shinozuka; M Robert-Guroff; T Shimada; Cy A Stein; Hiroaki Mitsuya; F Wong-Staal; J S Cohen; S Broder
Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(11):4244-8.
1989: S L Loke; Cy A Stein; X H Zhang; K Mori; M Nakanishi; C Subasinghe; J S Cohen; Leonard M Neckers
Characterization of oligonucleotide transport into living cells.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(10):3474-8.
1989: T Yano; M Linehan; P Anglard; Michael I Lerman; L N Daniel; Cy A Stein; C N Robertson; R LaRocca; Berton Zbar
Genetic changes in human adrenocortical carcinomas.
Journal of the National Cancer Institute 1989;81(7):518-23.
1989: Cy A Stein; R V LaRocca; R Thomas; N McAtee; Charles E Myers
Suramin: an anticancer drug with a unique mechanism of action.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(4):499-508.
1989: C Majumdar; Cy A Stein; J S Cohen; S Broder; Samuel H Wilson
Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide.
Biochemistry 1989;28(3):1340-6.
1989: Cy A Stein; J S Cohen
Antisense compounds: potential role in cancer therapy.
Important advances in oncology 1989;():79-97.
1988: M Matsukura; G Zon; K Shinozuka; Cy A Stein; Hiroaki Mitsuya; J S Cohen; S Broder
Synthesis of phosphorothioate analogues of oligodeoxyribonucleotides and their antiviral activity against human immunodeficiency virus (HIV).
Gene 1988;72(1-2):343-7.
1988: Cy A Stein; K Mori; S L Loke; C Subasinghe; K Shinozuka; J S Cohen; Leonard M Neckers
Phosphorothioate and normal oligodeoxyribonucleotides with 5'-linked acridine: characterization and preliminary kinetics of cellular uptake.
Gene 1988;72(1-2):333-41.
1988: Edward J Holland; Cy A Stein; A G Palestine; R LaRocca; C C Chan; T Kuwabara; Charles E Myers; R Thomas; N McAtee; Robert B Nussenblatt
Suramin keratopathy.
American journal of ophthalmology 1988;106(2):216-20.
1988: Cy A Stein; J S Cohen
Oligodeoxynucleotides as inhibitors of gene expression: a review.
Cancer research 1988;48(10):2659-68.
1988: Cy A Stein; C Subasinghe; K Shinozuka; J S Cohen
Physicochemical properties of phosphorothioate oligodeoxynucleotides.
Nucleic acids research 1988;16(8):3209-21.
1988: McDonald K Horne; Cy A Stein; R V LaRocca; Charles E Myers
Circulating glycosaminoglycan anticoagulants associated with suramin treatment.
Blood 1988;71(2):273-9.
1988: S L Loke; Cy A Stein; X Zhang; Mark I Avigan; J Cohen; L M Neckers
Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis.
Current topics in microbiology and immunology 1988;141():282-9.
1987: P Feuillan; M Raffeld; Cy A Stein; N Lipford; D Rehnquist; C E Meyers; R V LaRocca; G P Chrousos
Effects of suramin on the function and structure of the adrenal cortex in the cynomolgus monkey.
The Journal of clinical endocrinology and metabolism 1987;65(1):153-8.
1986: Cy A Stein; W Saville; R Yarchoan; S Broder; E P Gelmann
Suramin and function of the adrenal cortex.
Annals of internal medicine 1986;104(2):286-7.